This research paper from Anamul Haque published in the International Journal of Pharmaceutics reviews the development and use of lipid nanoparticles (LNPs) as delivery carriers for RNA-based therapeutics. The paper discusses the advantages and disadvantages of LNPs, including their ability to protect RNA from degradation, their strong transfection efficiency, and their low toxicity. The authors also provide a comprehensive analysis of the components of LNP formulations, including ionizable lipids, cholesterol, helper lipids, and PEGylated lipids, and examine the selection of the appropriate molar ratio of lipid components in LNPs. They highlight the use of LNPs in clinical trials for a variety of diseases, such as hereditary amyloidogenic transthyretin amyloidosis, COVID-19, and various cancers. The paper emphasizes the potential of LNPs as a promising therapeutic approach for a wide range of disease